Nocturia Due to Nocturnal Polyuria
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Sanwa Kagaku KenkyushoSK-1404
Ferring PharmaceuticalsDesmopressin
Clinical Trials (2)
Total enrollment: 1,212 patients across 2 trials
Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects
Start: Feb 2017Est. completion: Dec 2017125 patients
Phase 2Completed
Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia)
Start: May 2020Est. completion: Sep 20241,087 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.